Recombinant Human 4-1BB Ligand/TNFSF9 Protein

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

4-1BB Ligand (4-1BBL), also known as CD137L, is a type II transmembrane protein that belongs to the TNF superfamily of molecules and plays an important role in immune response activation (1). The 38 kDa human 4-1BB Ligand consists of an 25 aa cytoplasmic domain, a 23 aa transmembrane segment, and a 206 aa extracellular domain (ECD) (2). Within the ECD, human 4-1BB Ligand shares 34% aa sequence identity with mouse and rat 4-1BB Ligand. 4-1BB Ligand is expressed by activated B cells, monocytes, macrophages, dendritic cells (DC), T cells, lymphoma and multiple myeloma cells, hematopoietic stem cells, early myeloid progenitors, neurons, and astrocytes (3-9). A 26 kDa soluble form of 4-1BB Ligand can be released from the surface of activated cells and retains bioactivity (10).
4-1BB Ligand binds to 4-1BB/TNFRSF9/CD137 on activated CD4⁺ and CD8⁺ T cells, thymocytes, and NK cells as well as on monocytes, neutrophils, DC, and eosinophils. In response to 4-1BB Ligand binding, 4-1BB transduces a co-stimulatory signal that promotes the proliferation, activation, and survival of CD4⁺ and CD8⁺ T cells (4, 11, 12). T cell co-stimulation through CD28 is important for the initial T cell expansion, while 4-1BB acts later in the response (12, 13). 4-1BB Ligand function supports the survival and responsiveness of memory T cells during viral infection (13-15). Reverse signaling through 4-1BB Ligand on monocytes induces the production of inflammatory cytokines (5). On macrophages, 4-1BB Ligand associates in cis with TLR4 and enhances inflammatory cytokine production in response to TLR4 ligation (6). Its expression on early myeloid progenitor cells limits the development of dendritic cells, monocytes, and B cells (9).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: Bioassay, Surface Plasmon Resonance, Surface Plasmon Resonance (SPR.

Showing Publications 1 - 5 of 5.

Publications using 2295-4L	Applications	Species
SM Chin, CR Kimberlin, Z Roe-Zurz, P Zhang, A Xu, S Liao-Chan, D Sen, AR Nager, NS Oakdale, C Brown, F Wang, Y Yang, K Lindquist, YA Yeung, S Salek-Arda, J Chaparro-R Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab Nat Commun, 2018-11-08;9(1):4679. 2018-11-08 [PMID: 30410017] (Surface Plasmon Resonance, Human)	Surface Plasmon Resonance	Human
AW Clarke, L Poulton, D Shim, D Mabon, D Butt, M Pollard, V Pande, J Husten, J Lyons, C Tian, AG Doyle An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease MAbs, 2018-03-05;0(0):1-43. 2018-03-05 [PMID: 29436901] (Surface Plasmon Resonance (SPR, Human)	Surface Plasmon Resonance (SPR	Human
Madireddi S, Eun S, Lee S, Nemcovicova I, Mehta A, Zajonc D, Nishi N, Niki T, Hirashima M, Croft M Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med, 2014-06-23;211(7):1433-48. 2014-06-23 [PMID: 24958847] (Bioassay, Human)	Bioassay	Human
Moh M, Lorenzini P, Gullo C, Schwarz H Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling. FASEB J, 2013-04-25;27(8):2957-66. 2013-04-25 [PMID: 23620528] (Bioassay, Human)	Bioassay	Human
Lobito AA, Ramani SR, Tom I, Bazan JF, Luis E, Fairbrother WJ, Ouyang W, Gonzalez LC Murine insulin growth factor-like (IGFL) and human IGFL1 proteins are induced in inflammatory skin conditions and bind to a novel tumor necrosis factor receptor family member, IGFLR1. J. Biol. Chem., 2011-03-31;286(21):18969-81. 2011-03-31 [PMID: 21454693] (Surface Plasmon Resonance, Human)	Surface Plasmon Resonance	Human

Array 2295-4L

• 4-1BB Ligand/TNFSF9 Antibodies
• 4-1BB Ligand/TNFSF9 Lysate
• 4-1BB Ligand/TNFSF9 Proteins
• 4-1BB Ligand/TNFSF9 Proteins and Enzymes